Ilyang Pharm (007570) — Cash Flow Reinvestment Rate
Ilyang Pharm (007570) has a Cash Flow Reinvestment Rate of 3.94x as of June 2025, reinvesting ₩8.90 Billion (capex ₩3.32 Billion plus investments ₩-5.59 Billion) from operating cash flow of ₩2.26 Billion. Check 007570 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Ilyang Pharm Cash Flow Reinvestment Rate (2003–2024)
Historical reinvestment intensity for Ilyang Pharm across 12 annual periods. Explore 007570 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Ilyang Pharm (2003–2024)
Year-by-year capital reinvestment analysis for Ilyang Pharm. For live market cap and broader valuation context, see market value of Ilyang Pharm.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 13.86x | ₩77.80 Billion | ₩5.61 Billion | ₩40.62 Billion | ▲ +984.2% |
| 2023 | 1.28x | ₩17.05 Billion | ₩13.34 Billion | ₩6.47 Billion | ▲ +18.8% |
| 2022 | 1.08x | ₩32.20 Billion | ₩29.94 Billion | ₩4.08 Billion | ▲ +434.9% |
| 2021 | 0.20x | ₩13.48 Billion | ₩67.02 Billion | ₩12.91 Billion | ▲ +12.3% |
| 2020 | 0.18x | ₩10.29 Billion | ₩57.48 Billion | ₩10.17 Billion | ▼ -25.2% |
| 2019 | 0.24x | ₩8.67 Billion | ₩36.19 Billion | ₩2.17 Billion | ▲ +104.4% |
| 2018 | 0.12x | ₩2.59 Billion | ₩22.12 Billion | ₩1.55 Billion | ▼ -53.7% |
| 2017 | 0.25x | ₩7.60 Billion | ₩30.03 Billion | ₩3.78 Billion | ▼ -67.4% |
| 2016 | 0.78x | ₩20.98 Billion | ₩26.98 Billion | ₩10.31 Billion | ▲ +87.2% |
| 2015 | 0.42x | ₩16.72 Billion | ₩40.27 Billion | ₩16.07 Billion | ▼ -44.4% |
| 2014 | 0.75x | ₩13.92 Billion | ₩18.63 Billion | ₩13.89 Billion | ▲ +1715.2% |
| 2003 | 0.04x | ₩415.11 Million | ₩10.08 Billion | ₩415.11 Million | — |